Published: 7 October 2020
Author(s): Rupert Bauersachs
Issue: January 2021
Section: Commentary

After the pivotal phase 3 trials on venous thromboembolism (VTE) treatment with non-vitamin K antagonist oral anticoagulants (NOACs) had been performed some 10 years ago, these drugs have now become the standard anticoagulant treatment of VTE. While randomized controlled trials (RCT) carefully select patients to allow homogeneous comparisons between the randomized groups, real world evidence (RWE) is required from a much larger patient population with a high variation of clinical characteristics.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.